BioSpace News Archive

Sandoz Canada announced that it has launched two new generic alternatives to therapies that have been available under the brand names Coversyl and Coversyl Plus for the treatment of hypertension.

Controlled Substance Management Program recognized for helping to reduce opioid epidemic.

An aging population, the opioid public health crisis, and rising care costs are putting America’s health future at risk.

This new adaptation of Torch Insight will help strategists prepare for future recruitment and training.

Optera Therapeutics will develop cancer cell therapies discovered at MD Anderson and apply Berkeley Lights’ advanced cell therapy manufacturing systems with the goal of making these novel therapies accessible to all.

The warrants were exercised at $0.17, $0.20 or $0.30.

The oversubscribed round brings Atomwise’s total capital raised to more than $51 million.

ReShape Lifesciences Inc. (NASDAQ:RSLS), a developer of minimally invasive medical devices to treat obesity and metabolic diseases, today announced an exclusive federal government business channel sales agreement with Academy Medical, LLC to sell its ReShape Balloon™ and ReShape vBloc™ products to U.S. Department of Defense (DoD) medical facilities.

Agenus Inc. (NASDAQ: AGEN), an immuno-oncology company with a pipeline of immune checkpoint antibodies and cancer vaccines, will release its fourth quarter and full year 2017 financial results before the market opens on Thursday, March 15, 2018

Antibody-Drug Conjugate (ADC) SGN-CD48A Being Evaluated as Monotherapy, With Innovative Linker Technology That Highlights Continued Industry Leadership in ADCs